Bloomage Biotech(SH:688363) Nan Fang Du Shi Bao·2025-07-27 01:53Core Viewpoint - The article discusses the controversy surrounding Hyaluronic Acid giant Huaxi Bio (688363.SH), following accusations of financial fraud and bond issuance fraud made by a former employee, Li, who previously served as the marketing director of a subsidiary [1][2]. Group 1: Allegations and Company Response - Li, the former marketing director, accused Huaxi Bio of "financial fraud" and "fraudulent bond issuance" [1]. - In response, Huaxi Bio issued a strong statement denying the allegations, labeling them as "morally bankrupt fabrications" and asserting that they severely damage the company's reputation [1][7]. - The company reported that it has filed a police complaint against Li and intends to pursue legal action against those spreading the allegations [1][7]. Group 2: Historical Context and Internal Issues - Huaxi Bio revealed that in 2018, Li had embezzled 9 million yuan (approximately 1.3 million USD) through a third-party company he registered, which was meant for a brokerage firm [3][4]. - Following the discovery of this embezzlement, Huaxi Bio reported the incident to the police [3]. - Li had previously written an apology letter, promising to return the embezzled funds and offering an additional compensation of 1.5 million yuan (approximately 220,000 USD) [4]. Group 3: Management Changes and Company Performance - Recently, Huaxi Bio has undergone significant management changes, with the CEO emphasizing a strict governance approach to address internal issues and corruption [7][9]. - The company announced the resignation of three senior executives as part of its restructuring efforts [9]. - Huaxi Bio's financial performance has declined, reporting a revenue of 5.371 billion yuan (approximately 800 million USD) in 2024, a decrease of 11.6% year-on-year, and a net profit of 164 million yuan (approximately 24 million USD), down 72.27% year-on-year [10].